- Canine leishmaniasis prevention,
- Canine leishmaniasis treatment
Canine Leishmaniasis Management Market size was valued at USD x million in 2023 and is poised to grow at a CAGR of x% in 2024-2030. Canine leishmaniasis is an incurable multisystemic disease caused by the parasite, Leishmania infantum, which is transferred through the bite of a sandfly in tropical and subtropical countries, but direct transmission between dogs, and from pregnant dogs to their puppies, exists.
The rising incidence of canine leishmaniasis plays a pivotal role in driving the revenues of the canine leishmaniasis management market. The incidence of canine leishmaniasis is rising gradually worldwide. For instance, research suggests that the highest estimated ranged from 50 to 100 cases per 1000 dogs annually and were concentrated in the southeastern and southwestern regions of Spain, as well as the Balearic Islands. This increased burden of this disease drives the demand for the development of advanced treatment and diagnosis options. Diagnosis of this disease is often determined via serology, with quantitative serologic tests such as immunofluorescence assays or ELISA as confirmation. Treatment options are limited but the major protocols used for the treatment of leishmaniasis in dogs include the use of N-methylglucamine antimoniate or Miltefosine in combination with allopurinol. Moreover, rising government regulations are another powerful driver of the canine leishmaniasis management market. As health concerns about animal increases across the globe, the government is imposing several strict guidelines, which in turn necessitate the development of canine leishmaniasis management options. A nonprofit scientific association, LeishVet, has created regulations, primarily designed to assist veterinary clinicians in the management of canine leishmaniosis by suggesting standardized and rational approaches to the diagnosis, treatment, follow-up, control, and prevention of canine leishmaniosis. This strict regulation ultimately drives the growth of the canine leishmaniosis management market.
However, factors such as limited treatment options and lack of awareness pose significant challenges to the growth of the canine leishmaniasis management market. Meanwhile, the rise in research and development activities presents a significant opportunity for the growth of the canine leishmaniasis management market. Several key manufacturers are announcing launches to strengthen their market position.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The increasing pet ownership is a significant driver of growth in the canine leishmaniasis management market. As pet ownership across the world rises, the demand for concerns related to canine leishmaniasis disease increases, which in turn necessitates the development of advanced diagnosis and treatment options. As dogs are the main reservoir for this disease, pet owners are spending hugely to seek preventive measures to effectively manage leishmaniasis diseases in dogs, which boosts the demand for canine leishmaniasis management products. In addition, rising human health concerns are another major driver behind the growth of the canine leishmaniasis management market. Canine leishmaniasis, as it is a zoonotic disease, can be transferred to humans by a sandfly that has previously bitten an infected animal. Though this disease is not transferred directly from dog to human, it can play a crucial role in the transmission and spread of the parasite. It can have serious consequences if a human with a compromised immune system gets affected by leishmaniasis. Hence, using several repelllant and insecticides can prevent the bite of sandfly, which can ultimately protect both dogs and humans.
The canine leishmaniasis management market is projected to expand at a CAGR of x% during the forecast period.
Zoetis, Inc. (Pfizer) (U.S), Hertape Calier Saude Animal S.A. (Brazil), Virbac AH Inc. (France), Laboratories Leti (Spain), Bioiberica S.A. (Spain)
Asia Pacific is the fastest-growing region for canine leishmaniasis management market
The increasing investment in veterinary care, rising pet ownership, and rising awareness of animal health provide potential opportunities for companies to enhance their revenue over the forecast years.
The rising focus on research and development activities to develop effective diagnosis and treatment solutions stands out as a significant trend within the canine leishmaniasis management market.
1. Executive Summary |
2. Global Canine Leishmaniasis Management Market Introduction |
2.1. Global Canine Leishmaniasis Management Market Taxonomy |
2.2. Global Canine Leishmaniasis Management Market Definitions |
2.2.1. By Product Type |
2.2.2. By Disease |
2.2.3. By Administration |
2.2.4. By Distribution Channel |
2.2.5. By Region |
3. Global Canine Leishmaniasis Management Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Canine Leishmaniasis Management Market Dynamic Factors - Impact Analysis |
3.6. Global Canine Leishmaniasis Management Market Competition Landscape |
4. Global Canine Leishmaniasis Management Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Canine Leishmaniasis Management Market, By Product Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1. Vaccines |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) & (Volume, Units) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Antibiotics |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Polyene antibiotics (Amphotericin B) |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Marbofloxacin |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Miltefosine |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Meglumine Antimoniate |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Pentavalent antimonials |
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
5.8. Allopurinol combinations |
5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.8.3. Market Opportunity Analysis |
5.9. Paromomycin |
5.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.9.3. Market Opportunity Analysis |
6. Global Canine Leishmaniasis Management Market Forecast, By Disease, 2019 - 2023 and Forecast, 2024 - 2030 |
6.1. Visceral leishmaniasis |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Cutaneous leishmaniasis |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Mucocutaneous leishmaniasis |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Canine Leishmaniasis Management Market Forecast, By Administration, 2019 - 2023 and Forecast, 2024 - 2030 |
7.1. Oral |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Parenteral |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Topical |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Canine Leishmaniasis Management Market Forecast, By Application, 2019 - 2023 and Forecast, 2024 - 2030 |
8.1. Veterinary Clinics |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Veterinary Pharmacies |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacies |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. NGOs |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Others |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. Global Canine Leishmaniasis Management Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia-Pacific |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Middle East and Africa |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.6. Global Canine Leishmaniasis Management Market - Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Region 2024 - 2030 |
10. North America Canine Leishmaniasis Management Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
10.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Vaccines |
10.1.2. Antibiotics |
10.1.3. Polyene Antibiotics (Amphotericin B) |
10.1.4. Marbofloxacin |
10.1.5. Miltefosine |
10.1.6. Meglumine Antimoniate |
10.1.7. Pentavalent Antimonials |
10.1.8. Allopurinol Combinations |
10.1.9. Paromomycin |
10.1.10. Others |
10.2. Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. Visceral leishmaniasis |
10.2.2. Cutaneous leishmaniasis |
10.2.3. Mucocutaneous leishmaniasis |
10.3. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Oral |
10.3.2. Parenteral |
10.3.3. TopicalSkin |
10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Veterinary Clinics |
10.4.2. Veterinary Pharmacies |
10.4.3. Online Pharmacies |
10.4.4. NGOs |
10.4.5. Others |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.5.1. U.S. |
10.5.2. Canada |
10.6. North America Canine Leishmaniasis Management Market - Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2024 - 2030 |
10.7. North America Canine Leishmaniasis Management Market Dynamics Trends |
11. Europe Canine Leishmaniasis Management Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
11.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Vaccines |
11.1.2. Antibiotics |
11.1.3. Polyene Antibiotics (Amphotericin B) |
11.1.4. Marbofloxacin |
11.1.5. Miltefosine |
11.1.6. Meglumine Antimoniate |
11.1.7. Pentavalent Antimonials |
11.1.8. Allopurinol Combinations |
11.1.9. Paromomycin |
11.1.10. Others |
11.2. Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Visceral leishmaniasis |
11.2.2. Cutaneous leishmaniasis |
11.2.3. Mucocutaneous leishmaniasis |
11.3. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Oral |
11.3.2. Parenteral |
11.3.3. TopicalSkin |
11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Veterinary Clinics |
11.4.2. Veterinary Pharmacies |
11.4.3. Online Pharmacies |
11.4.4. NGOs |
11.4.5. Others |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.5.1. Germany |
11.5.2. UK |
11.5.3. France |
11.5.4. Spain |
11.5.5. Italy |
11.5.6. Russia |
11.5.7. Poland |
11.5.8. Rest of Europe |
11.6. Europe Canine Leishmaniasis Management Market - Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2024 - 2030 |
11.7. Europe Canine Leishmaniasis Management Market Dynamics – Trends |
12. Asia-Pacific Canine Leishmaniasis Management Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
12.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Vaccines |
12.1.2. Antibiotics |
12.1.3. Polyene Antibiotics (Amphotericin B) |
12.1.4. Marbofloxacin |
12.1.5. Miltefosine |
12.1.6. Meglumine Antimoniate |
12.1.7. Pentavalent Antimonials |
12.1.8. Allopurinol Combinations |
12.1.9. Paromomycin |
12.1.10. Others |
12.2. Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Visceral leishmaniasis |
12.2.2. Cutaneous leishmaniasis |
12.2.3. Mucocutaneous leishmaniasis |
12.3. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Oral |
12.3.2. Parenteral |
12.3.3. TopicalSkin |
12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Veterinary Clinics |
12.4.2. Veterinary Pharmacies |
12.4.3. Online Pharmacies |
12.4.4. NGOs |
12.4.5. Others |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.5.1. Japan |
12.5.2. China |
12.5.3. India |
12.5.4. ASEAN |
12.5.5. Australia & New Zealand |
12.5.6. Rest of Asia-Pacific |
12.6. Asia-Pacific Canine Leishmaniasis Management Market - Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2024 - 2030 |
12.7. Asia-Pacific Canine Leishmaniasis Management Market Dynamics Trends |
13. Latin America Canine Leishmaniasis Management Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
13.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Vaccines |
13.1.2. Antibiotics |
13.1.3. Polyene Antibiotics (Amphotericin B) |
13.1.4. Marbofloxacin |
13.1.5. Miltefosine |
13.1.6. Meglumine Antimoniate |
13.1.7. Pentavalent Antimonials |
13.1.8. Allopurinol Combinations |
13.1.9. Paromomycin |
13.1.10. Others |
13.2. Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.2.1. Visceral leishmaniasis |
13.2.2. Cutaneous leishmaniasis |
13.2.3. Mucocutaneous leishmaniasis |
13.3. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Oral |
13.3.2. Parenteral |
13.3.3. TopicalSkin |
13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Veterinary Clinics |
13.4.2. Veterinary Pharmacies |
13.4.3. Online Pharmacies |
13.4.4. NGOs |
13.4.5. Others |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.5.1. Brazil |
13.5.2. Mexico |
13.5.3. Argentina |
13.5.4. Rest of Latin America |
13.6. Latin America Canine Leishmaniasis Management Market - Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2024 - 2030 |
13.7. Latin America Canine Leishmaniasis Management Market Dynamics Trends |
14. Middle East and Africa Canine Leishmaniasis Management Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
14.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.1.1. Vaccines |
14.1.2. Antibiotics |
14.1.3. Polyene Antibiotics (Amphotericin B) |
14.1.4. Marbofloxacin |
14.1.5. Miltefosine |
14.1.6. Meglumine Antimoniate |
14.1.7. Pentavalent Antimonials |
14.1.8. Allopurinol Combinations |
14.1.9. Paromomycin |
14.1.10. Others |
14.2. Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.2.1. Visceral leishmaniasis |
14.2.2. Cutaneous leishmaniasis |
14.2.3. Mucocutaneous leishmaniasis |
14.3. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.3.1. Oral |
14.3.2. Parenteral |
14.3.3. TopicalSkin |
14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.4.1. Veterinary Clinics |
14.4.2. Veterinary Pharmacies |
14.4.3. Online Pharmacies |
14.4.4. NGOs |
14.4.5. Others |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
14.5.1. Gulf Cooperation Council (GCC) Countries |
14.5.2. Israel |
14.5.3. South Africa |
14.5.4. Rest of MEA |
14.6. MEA Canine Leishmaniasis Management Market - Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2024 - 2030 |
14.7. MEA Canine Leishmaniasis Management Market Dynamics Trends |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, Product Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. Zoetis, Inc. (Pfizer) (U.S) |
15.2.2. Ceva Sant Animale (Hertape Calier Saude Animal S.A) |
15.2.3. Virbac AH Inc. (France) |
15.2.4. Laboratories Leti (Spain) |
15.2.5. Bioiberica S.A. (Spain) |
15.2.6. Sanofi S.A. (France) |
16. Research Methodology |
17. Key Assumptions and Acronyms |